Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

G. Von Minckwitz, M. Procter, E. de Azambuja, D. Zardavas, M. Benyunes, G. Viale, T. Suter, A. Arahmani, N. Rouchet, E. Clark, A. Knott, I. Lang, C. Levy, D.A. Yardley, J. Bines, R.D. Gelber, M. Piccart, J. Baselga, [ as member of APHINITY Steering Committee and Investigators], V. Di Lauro

Research output: Contribution to journalArticlepeer-review

Abstract

APPENDICE;INTERNAZIONALE
Original languageEnglish
Pages (from-to)122-131
Number of pages10
JournalNew Engl J Med
Volume377
Issue number2
Publication statusPublished - Jul 13 2017

Keywords

  • breast cancer
  • pertuzumab
  • trastuzumab

Fingerprint Dive into the research topics of 'Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer'. Together they form a unique fingerprint.

Cite this